Yi Yin, Jun Xiao, Liyu Su, Rongbo Lin. "An early on-treatment "coordinated inflammatory niche" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.3600